Investigators

Summary

My research has been rooted in developing and applying new technologies involving “high content” imaging methods to biomedical challenges. We have been applying quantitative systems pharmacology (QSP) to multiple disease areas including liver diseases and solid tumor cancers.  My interests include integrating QSP with patient microphysiology systems (MPS) to generate pathophysiological experimental and computational models to create a powerful paradigm in drug discovery and development. The latter has led to developing patient digital twins and patient biomimetic twins for liver diseases together with creating the BioSystics-Analytics Platform to manage, analyze, share and computationally model patient and biomimetic twin data. We spun-off BioSystics that merged with Nortis, Inc. to form NUMA Biosciences, a precision medicine company. In addition, our development of next generation spatial biology analytics for highly multiplexed fluorescence image data from patients led to the formation of PredxBio to address patient heterogeneity in drug discovery and development.